JO3137B1 - أملاح وأشكال جديدة لمثبط إنزيم سينثاز أو أروماتاز ثنائي هيدروبيرولو [2،1-c] إيميدازوليل ألدوستيرون - Google Patents

أملاح وأشكال جديدة لمثبط إنزيم سينثاز أو أروماتاز ثنائي هيدروبيرولو [2،1-c] إيميدازوليل ألدوستيرون

Info

Publication number
JO3137B1
JO3137B1 JOP/2013/0014A JOP20130014A JO3137B1 JO 3137 B1 JO3137 B1 JO 3137B1 JO P20130014 A JOP20130014 A JO P20130014A JO 3137 B1 JO3137 B1 JO 3137B1
Authority
JO
Jordan
Prior art keywords
salts
dihydropyrrolo
imidazolyl
aldosterone synthase
new forms
Prior art date
Application number
JOP/2013/0014A
Other languages
Arabic (ar)
English (en)
Inventor
M Loeser Eric
Allen Sutton Paul
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47604250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3137(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3137B1 publication Critical patent/JO3137B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JOP/2013/0014A 2012-01-17 2013-01-15 أملاح وأشكال جديدة لمثبط إنزيم سينثاز أو أروماتاز ثنائي هيدروبيرولو [2،1-c] إيميدازوليل ألدوستيرون JO3137B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261587280P 2012-01-17 2012-01-17

Publications (1)

Publication Number Publication Date
JO3137B1 true JO3137B1 (ar) 2017-09-20

Family

ID=47604250

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0014A JO3137B1 (ar) 2012-01-17 2013-01-15 أملاح وأشكال جديدة لمثبط إنزيم سينثاز أو أروماتاز ثنائي هيدروبيرولو [2،1-c] إيميدازوليل ألدوستيرون

Country Status (40)

Country Link
US (2) US9334276B2 (en:Method)
EP (1) EP2804863B1 (en:Method)
JP (1) JP5749410B2 (en:Method)
KR (2) KR20140093726A (en:Method)
CN (1) CN104039793B (en:Method)
AP (1) AP2014007762A0 (en:Method)
AR (1) AR089728A1 (en:Method)
AU (1) AU2013209952B2 (en:Method)
BR (1) BR112014017260A8 (en:Method)
CA (1) CA2863339C (en:Method)
CL (1) CL2014001863A1 (en:Method)
CO (1) CO7000775A2 (en:Method)
CR (1) CR20140345A (en:Method)
CU (1) CU20140086A7 (en:Method)
CY (1) CY1117914T1 (en:Method)
DK (1) DK2804863T3 (en:Method)
EA (1) EA026232B1 (en:Method)
ES (1) ES2564143T3 (en:Method)
GT (1) GT201400155A (en:Method)
HR (1) HRP20160178T1 (en:Method)
HU (1) HUE026984T2 (en:Method)
IL (1) IL233541B (en:Method)
IN (1) IN2014DN06781A (en:Method)
JO (1) JO3137B1 (en:Method)
MA (1) MA35858B1 (en:Method)
MX (1) MX2014008686A (en:Method)
NZ (1) NZ626277A (en:Method)
PE (1) PE20142358A1 (en:Method)
PH (1) PH12014501638A1 (en:Method)
PL (1) PL2804863T3 (en:Method)
RS (1) RS54589B1 (en:Method)
SG (1) SG11201404061YA (en:Method)
SI (1) SI2804863T1 (en:Method)
SM (1) SMT201600083B (en:Method)
TN (1) TN2014000256A1 (en:Method)
TW (1) TWI609869B (en:Method)
UA (1) UA114803C2 (en:Method)
UY (1) UY34576A (en:Method)
WO (1) WO2013109514A1 (en:Method)
ZA (1) ZA201404314B (en:Method)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011205290C1 (en) * 2010-01-14 2014-11-06 Recordati Ag Use of an adrenal hormone-modifying agent
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
SI3166596T1 (sl) * 2014-07-07 2018-10-30 Novartis Ag Farmacevtske odmerne oblike
HUE054248T2 (hu) 2015-01-29 2021-08-30 Recordati Ag Eljárás kondenzált imidazo-származékok elõállítására
US20160287565A1 (en) * 2015-04-06 2016-10-06 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production
EP3532056A1 (en) * 2016-10-27 2019-09-04 Damian Pharma AG Aldosterone synthase inhibitor
WO2018078049A1 (en) * 2016-10-27 2018-05-03 Damian Pharma Ag Aldosterone synthase inhibitor
WO2019211394A1 (en) 2018-05-03 2019-11-07 Damian Pharma Ag R-fadrozole for use in the treatment of aldostonerism

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1315449A (en) * 1918-11-15 1919-09-09 Frank B Yingling Shaper-feed.
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US5066656A (en) 1989-11-01 1991-11-19 Janssen Pharmaceutica N.V. Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
MTP1076B (en) 1990-01-12 1991-09-30 Ciba Geigy Ag Hemihydrate
CA2127689A1 (en) 1992-01-27 1993-08-05 Marcel A. C. Janssen Pyrroloimidazolyl and imidazopyridinyl substituted 1h-benzimidazole derivatives as aromatase inhibitors
CA2505752A1 (en) 2002-11-18 2004-06-03 Novartis Ag Imidazo[1,5a]pyridine derivatives and methods for treating aldosterone mediated diseases
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
CN101578272A (zh) 2006-12-18 2009-11-11 诺瓦提斯公司 1-取代的咪唑衍生物和它们作为醛固酮合酶抑制剂的用途
US8575160B2 (en) 2009-11-30 2013-11-05 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
AU2011205290C1 (en) * 2010-01-14 2014-11-06 Recordati Ag Use of an adrenal hormone-modifying agent

Also Published As

Publication number Publication date
HRP20160178T1 (hr) 2016-03-25
TN2014000256A1 (en) 2015-09-30
JP5749410B2 (ja) 2015-07-15
PH12014501638B1 (en) 2014-10-13
NZ626277A (en) 2015-10-30
CO7000775A2 (es) 2014-07-21
CU20140086A7 (es) 2014-12-26
IL233541A0 (en) 2014-08-31
IL233541B (en) 2018-12-31
PL2804863T3 (pl) 2016-06-30
RS54589B1 (sr) 2016-08-31
PE20142358A1 (es) 2015-01-30
BR112014017260A2 (pt) 2017-06-13
MX2014008686A (es) 2014-08-27
CR20140345A (es) 2014-09-09
TWI609869B (zh) 2018-01-01
EP2804863B1 (en) 2015-12-02
ES2564143T8 (es) 2020-11-18
US20140364470A1 (en) 2014-12-11
AU2013209952A1 (en) 2014-07-24
EP2804863A1 (en) 2014-11-26
JP2015503627A (ja) 2015-02-02
UA114803C2 (uk) 2017-08-10
ES2564143T3 (es) 2016-03-18
AU2013209952B2 (en) 2016-09-01
CL2014001863A1 (es) 2014-11-07
UY34576A (es) 2013-09-02
CY1117914T1 (el) 2017-05-17
SG11201404061YA (en) 2014-08-28
EA026232B1 (ru) 2017-03-31
AR089728A1 (es) 2014-09-10
US20160176883A1 (en) 2016-06-23
CA2863339C (en) 2021-03-23
SI2804863T1 (sl) 2016-05-31
GT201400155A (es) 2017-09-28
IN2014DN06781A (en:Method) 2015-05-22
DK2804863T3 (en) 2016-03-07
US9334276B2 (en) 2016-05-10
KR20140093726A (ko) 2014-07-28
EA201491374A1 (ru) 2014-12-30
PH12014501638A1 (en) 2014-10-13
ZA201404314B (en) 2015-08-26
CA2863339A1 (en) 2013-07-25
WO2013109514A1 (en) 2013-07-25
SMT201600083B (it) 2016-04-29
BR112014017260A8 (pt) 2017-07-04
CN104039793B (zh) 2017-05-10
HUE026984T2 (en) 2016-08-29
HK1198536A1 (en) 2015-05-15
AP2014007762A0 (en) 2014-07-31
KR20140141687A (ko) 2014-12-10
CN104039793A (zh) 2014-09-10
MA35858B1 (fr) 2014-12-01
TW201335161A (zh) 2013-09-01

Similar Documents

Publication Publication Date Title
PH12014501638A1 (en) New forms and salts of a dihydropyrrolo [1,2-c] imidazolyl aldosterone synthase or aromatase inhibitor
PL3808749T3 (pl) Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych
AP3847A (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
IN2014DN07384A (en:Method)
MX2015007921A (es) Compuestos heterociclicos novedosos como inhibidores de bromodominio.
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
MX352927B (es) Derivados de 1h-pirrolo [2,3-b] piridina y su uso como inhibidores de quinasa.
MY172308A (en) Bicyclic pyrazinone derivatives
HRP20182007T1 (hr) Derivati 3-okso-2,3,5,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirimidina za liječenje respiratornih bolesti
IL246034A0 (en) History of [1,2,4]triazolo[1,5-a]pyrimidine as protozoan proteasome inhibitors for the treatment of parasitic diseases such as Jericho
MX340536B (es) Terapia direccionada al receptor del factor de crecimiento epidermico (egfr).
SG10201408059QA (en) 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases
TN2013000377A1 (en) Thieno [2, 3-d] pyrimidine derivatives and their use to treat arrhythmia